GeneralConnection.com ➔ Dictionary
Dictionary Search

myeloma

Synonyms

Noun

1. malignant tumor

2. malignant neoplasm, metastatic tumor

Usage
Iopofosine I 131 Shows Safety, Antitumor Activity in R/R Multiple Myeloma - Targeted Oncology
ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite Maintenance Treatment vs 2-Years - The ASCO Post
FDA Approves First On-Body Injector for Multiple Myeloma Treatment - Oncology Nursing News
An Edwardsville teacher spent 27 years helping students. Now they're helping him - The Edwardsville Intelligencer
Immune ecotypes may explain multiple myeloma outcomes missed by disease staging - UT MD Anderson
US FDA approves isatuximab-irfc as a subcutaneous injection for multiple myeloma indications - Oncology Central
Trial Questions Continuous Maintenance in Newly Diagnosed Myeloma - MedPage Today
Dr Cerchione on the FDA Approval of Subcutaneous Isatuximab in Myeloma - OncLive
Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy - Mayo Clinic News Network
IMF Shares New Study Results on Multiple Myeloma Maintenance Therapy - Oncodaily
Practical Management Considerations in Newly Diagnosed Multiple Myeloma - CancerNetwork
Stopping myeloma maintenance after two years shows no survival loss in trial - Medical Xpress
FDA sets 2027 date for decision on myeloma combo treatment - Rare Cancer News
How AON Built an Outpatient BiTE Therapy Program for Multiple Myeloma - Pharmacy Times
Multiple Myeloma Care: Innovative Nursing Strategies and Patient Support - Oncology Nursing News
Subcutaneous Isatuximab Approval Expands Options in Multiple Myeloma - CancerNetwork
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma - Targeted Oncology
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma - OncLive
FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma - CancerNetwork
Selecting BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma - CancerNetwork
Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma - Oncology Nurse Advisor
Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma - Yahoo Finance
Combination treatment strategy uses cells' waste removal functions to dismantle multiple myeloma - News-Medical
Mayo Clinic study: less myeloma treatment can be just as effective - KIMT
Remote Patient Monitoring in Myeloma: How Technology Is Transforming Bispecific Antibody Management - Pharmacy Times
Real-World Tolerability of Cilta-Cel Aligns With Multiple Myeloma Trials - Targeted Oncology
Greene County father shares journey with rare cancer - WHIO TV
Interpreting Efficacy Endpoints for BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma - CancerNetwork
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial - Nature
Teclistamab Improves Outcomes in Relapsed Multiple Myeloma - University of Miami
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma - The American Journal of Managed Care® (AJMC®)
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma Indications - Oncology News Central
Rahul Bhargava: New MyGIG Initiative Aims to Redefine Precision Care in Multiple Myeloma - Oncodaily
Striving for a cure for multiple myeloma: What HCPs need to know - Johnson & Johnson
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma - The American Journal of Managed Care® (AJMC®)
Gut microbiome emerges as key clue to cancer drug side effects - Medical Xpress
Improving how multiple myeloma is understood and treated - Mayo Clinic News Network
Reflecting on CAR T for First Relapse in Multiple Myeloma - Targeted Oncology
Facing the unexpected: Clay Johnson’s fight, faith, and strength through cancer - Emanuel County Live
Relapsed/Refractory Multiple Myeloma: Rationale and Design of the MonumenTAL-3 Study - CancerNetwork
Smoldering multiple myeloma in transition: redefining early myeloma in the modern era - Nature
Multiple Myeloma: Diagnosis and Treatment - American Academy Of Family Physicians | AAFP
FDA Approves Subcutaneous Isatuximab in Multiple Myeloma - CancerNetwork
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial - Nature
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026 - OncLive
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease - Bristol Myers Squibb
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium | Blood Cancer Journal - Nature
Wearable Devices May Help Detect CRS Earlier in Patients With Myeloma Receiving CAR T-Cell Therapy - The ASCO Post
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma - Targeted Oncology
The Future of Myeloma Treatment: Ajai Chari, MD - The American Journal of Managed Care® (AJMC®)
Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma - Medical Professionals Reference
FDA Approves Subcutaneous Isatuximab-irfc for Multiple Myeloma - Oncology Nursing News
FDA Approves Subcutaneous Isatuximab for MM Indications - Medscape
FDA approves under-the-skin option for multiple myeloma treatment - Rare Cancer News
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy - ASCO Publications
Is a Functional Cure for Multiple Myeloma Within Reach? - Cure Today
Multiple Myeloma Trial Explores Immunotheraphy Option - Froedtert & MCW
Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better - Stock Titan
Multiple Myeloma: Shedding Light on a Rare but Complex Blood Cancer - Pfizer
Bloodlines Series: What Is Smoldering Myeloma? - American Association for Cancer Research (AACR)
Teclistamab Plus Daratumumab: MajesTEC-3 Data, Patient Selection, and the Evolving Role of Bispecifics in RRMM - The American Journal of Managed Care® (AJMC®)
Defining cure for multiple myeloma: Lu Anna’s story - Roswell Park Comprehensive Cancer Center
FDA Approves Sarclisa Escena as a New Under the Skin Treatment Option for Multiple Myeloma - Cure Today
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word - CancerNetwork
Minimal Residual Disease Testing in Multiple Myeloma - ASCO Daily News
Extending survival with innovations in multiple myeloma therapy - Penn Medicine
Diabetes mellitus in multiple myeloma and related plasma cell disorders: a review of risk, prognosis, and outcomes - Nature
Enhanced dynamic risk stratification of smoldering multiple myeloma - Nature
Are multiple myeloma rates higher in Western New York? - Roswell Park Comprehensive Cancer Center
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D | Leukemia - Nature
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial - Nature
When Should Oncologists Treat Smoldering Multiple Myeloma? - ASCO Daily News
Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials - Nature
Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma - The ASCO Post
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study - Nature
CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target - Nature
Myeloma: How AI Is Redrawing the Map of Cancer Care - University of Miami
How Does Multiple Myeloma Kill You? - Health: Trusted and Empathetic Health and Wellness Information
Elranatamab Shows Strong Efficacy Signal in Smoldering Multiple Myeloma - CancerNetwork
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma - Oncodaily
CAR-T Moves to the Front Line: Rethinking the Multiple Myeloma Sequence - CancerNetwork
Cellectar Biosciences Announces Publication of Phase 1 Data for Iopofosine I 131 in Relapsed/Refractory Multiple Myeloma - Quiver Quantitative
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma - Nature
Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma - Nature
Autologous Stem Cell Transplantation in Multiple Myeloma: Is It Still the Gold Standard? - CancerNetwork
Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3′U-tRF - Nature
Bristol Myers files mezigdomide myeloma application - grafa.com
Mezigdomide Triplet Cuts Progression Risk by 52% in R/R Myeloma - Targeted Oncology
Real-world analysis of multiple myeloma treatments in England using the Cancer Analysis System registry - Nature
MAIA Long-Term Outcomes in Newly Diagnosed Multiple Myeloma - CancerNetwork
Charting Progress, Changing Outcomes: The Evolution of Multiple Myeloma Care - Sanofi
Leaving the Bone Marrow: Extramedullary Disease in Multiple Myeloma - Cancer Nursing Today
Peripheral blood cfDNA detection using clonoSEQ assay in multiple myeloma is concordant with bone marrow and clinical biomarkers - Nature
Impact of clinical surveillance on myeloma-related complications in patients with precursor plasma cell disorders - Nature
Talquetamab Combinations in Relapsed or Refractory Myeloma - The ASCO Post
Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma - The University of Alabama at Birmingham
Multiple Myeloma: Understanding the Unseen Burdens Beyond Disease - Sanofi
New treatment combination delays multiple myeloma progression and may improve survival, study finds - Atrium Health Wake Forest Baptist
The Multiple Myeloma Revolution Happening Right Now: Swarup Kumar, MD - The American Journal of Managed Care® (AJMC®)
Bispecific Sequencing, CRS Risk, and CELMoDs: Navigating the Evolving Second-Line RRMM Landscape - The American Journal of Managed Care® (AJMC®)
Foreign Language Equivalents
Foreign Language Equivalents of 'myeloma'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
mye;oma,   myeloa,   myelo,a,   myleoma,   myekoma,   myelpma,   myelomaa,   myelima,   mmyeloma,   yeloma,   myrloma,   mteloma,   ymeloma,   myeloam,   myelomma,   nyeloma,   myelloma,   myyeloma,   myloma,   myelmoa,   meyloma,   myelooma,   myeloms,   myelom,   ,yeloma,   myeeloma,   myelma,   myelona,   myeoma,   mueloma,   meloma,   myeolma,   mywloma
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z